Market cap
$2.3b
End-of-day close multiplied by current shares on issue.
Investment property revaluations drove the headline gain while capex at 55.9% of revenue absorbed most of the operating cash flow expansion.
Comparable chart history for this briefing.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$2.3b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
44.25x
Enterprise value compared with recent EBITDA.
P/FCF
12.41x
Market cap compared with recent free cash flow.
P/B
0.57x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY22 vs FY21
Revenue
$508.8m
+11.6% ↑ vs $455.8m
Net profit after tax
$692.9m
+63.8% ↑ vs $423.1m
Net cash inflow from operating activities
$586m
+41.8% ↑ vs $413.1m
Profit before tax
$722.1m
+75.9% ↑ vs $410.5m
Cash and cash equivalents
$28.3m
+40.3% ↑ vs $20.2m
Total assets
$11b
+19.6% ↑ vs $9.2b
What changed
That gap is the most material feature of the result: revenue grew 11.6% to $508.8m, which is much closer to the underlying earnings shape than the IFRS headline.
Operating cash flow rose 41.8% to $586.0m, helped by new sales and resales activity. However, capex stepped up 29.6% to $284.3m, lifting capex intensity to 55.9% of revenue. Gross borrowings rose 13.3% to $2.6b and trade debtors rose 31.3% to $654.8m, well ahead of revenue growth. Australia's revenue share rose to 14.4% from 11.1% as that segment grew 45.8%.
What matters
The 63.8% NPAT print is dominated by non-cash fair-value movements on investment property, not operating performance. The disclosed underlying profit growth of 13.6% is the cleaner read on the business, and that figure sits broadly in line with revenue growth of 11.6%. Anchoring on the reported number overstates the rate of operating improvement materially.
Capital intensity is rising, not falling. Capex of $284.3m equals 55.9% of revenue, up from 48.1% prior, and free cash flow pre-lease of $301.7m covers only 43.5% of reported NPAT. The business is in heavy build-out mode, funded by a combination of internal cash, resales, and incremental borrowings of roughly $302m. This matters because reported earnings include large unrealised gains that cannot fund the build programme.
Receivables ballooned faster than revenue. Trade debtors rose 31.3% to $654.8m against 11.6% revenue growth, lifting receivable days to 469.7 from 399.3. For a retirement village operator a large receivable balance is structural (occupation-right balances and resale-related amounts), but the rate of growth still warrants attention because it ties up incremental working capital and limits headline cash conversion.
Expectations
The HY22 interim disclosed first-half NPAT of $281.5m, which is 40.6% of the full-year reported figure, implying an H2-weighted earnings shape — consistent with valuation-driven profits crystallising at year end rather than a step-up in underlying trading. Revenue was more evenly split (48.7% in H1), reinforcing that the H2 skew is largely a fair-value phenomenon.
The result does support continued top-line growth at low double-digit rates and material expansion in Australia, but it does not provide forward work or development pipeline data that would let an outside reader test the durability of the build programme behind the rising capex.
Quality of result
Underlying profit growth of 13.6% is broadly cash-relevant and matches the revenue and operating cash flow direction. The reported +63.8% NPAT is not — it is driven by unrealised property revaluations and is amplified by a negative effective tax rate of -4.0% (versus -3.1% prior), so PBT growth at +75.9% actually exceeded NPAT growth.
The cash side is genuine but consumed by reinvestment. Operating cash flow of $586.0m is strong, but pre-lease free cash flow of $301.7m has to absorb a $302.6m increase in gross borrowings to keep the development programme funded. Equity rose 21.4% and ROE improved to 20.2% from 14.9%, but that ROE benefits from the same revaluation gains driving the NPAT line; the underlying return on capital deployed in operations is materially lower.
Unresolved
This briefing cannot assess the development pipeline economics, embedded value of the deferred management fee receivable, or the sustainability of the property revaluation assumptions because none of those disclosures were supplied in the source extracts.
Chat
Ask follow-up questions about Ryman Healthcare's FY22 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Ryman Healthcare Limited - Annual Report 2022
FY22 / financial reportRyman Healthcare Limited - Annual Report 2021
FY21 / financial reportRyman Healthcare Limited - Announcement Numbers - 30 September 2021
HY22 / financial reportRyman Healthcare Limited - Media Release and Key Statistics - 30 September 2021
HY22 / media releaseRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 12.1pp, with a distortion flag in the result.
Revenue growth context
Revenue growth was 11.6% for this reporting period.
ROE and capital efficiency
ROE was 20.2%, +5.3pp versus the prior comparable period.
Working-capital pressure
Inventory days were 19 days, -2 days versus the prior comparable period.
Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.